Zydus Wellness Limited (ZYDUSWELL)

Fast Moving Consumer Goods · Food Products · NSE · Updated 15 July 2026

₹576.05 ↓ 71.51% (1Y)

🎯 Key Takeaways

Zydus Wellness Limited is in a strategic transition phase, shifting from a mature FMCG portfolio toward high-growth health and wellness segments, particularly vitamins, minerals, and supplements (VMS). The company is actively expanding its international footprint with the incorporation of a European subsidiary, signaling a long-term ambition to reposition beyond domestic commodity FMCG performance.
Revenue declined 6.3% QoQ to ₹462 in Q3FY25.
⚠️ Sustained decline in core FMCG revenue and margins, with no clear inflection point yet.

Market Cap

₹15,976

P/E Ratio

49.1

Div Yield

0.00%

Promoter

0.0%

✨ Ask AI About ZYDUSWELL 📊 Interactive Charts

📖 The Story

Zydus Wellness Limited is in a strategic transition phase, shifting from a mature FMCG portfolio toward high-growth health and wellness segments, particularly vitamins, minerals, and supplements (VMS). The company is actively expanding its international footprint with the incorporation of a European subsidiary, signaling a long-term ambition to reposition beyond domestic commodity FMCG performance.

📰 What's Happening

In Q3FY25, the company reported a sharp revenue decline to ₹462 crore from ₹841 crore in Q1FY25, with operating profit collapsing to ₹19 crore and OPM dropping to 3.2% from 18.5%. This downward trend continued from the strong performance in FY24, where margins and profits were significantly higher. Concurrently, management incorporated Zydus Wellness (EU) Limited in Ireland to establish a foothold in the European VMS market. Promoter Samar Babubhai Patel made two small open market purchases in mid-June 2026, acquiring 1,500 shares in total, which slightly increased his stake but did not alter holding percentage. No board meetings or major strategic updates were disclosed recently.

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

Metric	Q4FY23	Q1FY24	Q2FY24	Q3FY24	Q4FY24	Q1FY25	Q2FY25	Q3FY25
Revenue	713	702	440	403	783	841	493	462
Operating Profit	138	105	21	16	166	160	30	19
OPM %	20.3%	16.6%	3.8%	3.1%	20.7%	18.5%	4.0%	3.2%
Net Profit	145	110	6	0	150	148	21	6
EPS	₹22.84	₹17.35	₹0.93	₹0.05	₹23.62	₹23.21	₹3.28	₹1.01

The financial trajectory shows a clear deterioration in core profitability over the past four quarters, with revenue and margins declining sharply from the peak seen in Q1FY25. This suggests the business is undergoing structural pressure, possibly due to market saturation, competitive headwinds, or shifting consumer preferences in the FMCG space. The sharp drop in operating profit and margins in Q3FY25 contrasts with earlier strength, indicating that current performance may not be sustainable without strategic intervention or new growth engines.

🔮 Management Outlook & What's Next

There is no publicly available forward guidance or explicit outlook from management in the latest filings. While the incorporation of the European subsidiary is presented as a strategic step for future growth in the VMS space, no timeline, revenue targets, or investment plans have been disclosed. Management has not provided commentary on recovery expectations or margin improvement pathways in the recent disclosures.

Extracted from official company announcements. Not StockFin.ai's opinion.

⚖️ Peer Comparison — Food Products

Company	MCap (₹ Cr)	P/E	ROCE	ROE	D/E
Nestle India Limited	2.76 L Cr	84.6	93.6%	81.3%	0.19
Britannia Industries Limited	1.30 L Cr	53.9	60.6%	55.5%	0.28
Hatsun Agro Product Limited	20,977	60.2	—	—	—
Avanti Feeds Limited	18,028	37.5	—	—	—
Bikaji Foods International Limited	16,776	61.5	—	—	—
Zydus Wellness Limited	15,976	49.1	—	—	—
EID Parry India Limited	14,042	9.2	—	—	—
Godrej Agrovet Limited	10,960	26.3	—	—	—
The Bombay Burmah Trading Corporation Limited	10,625	5.0	—	—	—
Orkla India Limited	8,647	—	—	—	—

🔗 Peer Stock Analyses

NESTLEIND BRITANNIA HATSUN AVANTIFEED BIKAJI

⚠️ Risk Factors

1. Sustained decline in core FMCG revenue and margins, with no clear inflection point yet. 2. High valuation (P/E of 49.1) despite weakening financial performance, making the stock vulnerable to earnings misses. 3. Strategic pivot to VMS and international markets lacks execution clarity or near-term financial contribution. 4. Market sentiment remains weak, reflected in a -71.51% one-year return, suggesting deteriorating investor confidence.

📋 Recent Filings

🧠 Analyst's Read

Investors should monitor upcoming quarterly results for signs of stabilization in the core business or early traction from the European subsidiary. The key inflection point will be whether new product launches or international sales begin contributing meaningfully to revenue and margins. Until then, the company remains in a high-risk transition phase with execution risk dominating the narrative.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

2 free AI queries per day.

✨ Deep Dive with AI on ZYDUSWELL

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-07-15.

📡 Get AI alerts when ZYDUSWELL files new disclosures

Track ZYDUSWELL filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track ZYDUSWELL — Free

Free account · 2 AI queries/day